Faslodex

Type: Product
Name: Faslodex
First reported Aug 19 2014 - Updated 18 hours ago - 1 reports

Pfizer Submits Palbociclib Marketing Application to the FDA

Pfizer Inc. ( PFE - Analyst Report ) announced that it has submitted the marketing application for its oncology candidate, palbociclib, to the FDA. The company is looking to get the candidate approved in combination with Novartis’ ( NVS - Analyst ... [Published Zacks.com - Aug 19 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

AstraZeneca (AZN) Beats on Q2 Earnings, Guidance Raised

AstraZeneca ( AZN ) reported second-quarter 2014 core earnings of $1.30 per American Depositary Share ( ADS ) beating the Zacks Consensus Estimate of $1.13. Earnings were also up 13% (at constant exchange rates or CER) year over year buoyed by higher ... [Published Yahoo! Finance - Aug 01 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

AZ upgrades its forecast for 2014

AstraZeneca Plc has upgraded its financial guidance for 2014 following an increase in revenue in the second quarter and the successful launch of a new medicine for Type 2 diabetes in the US. Sales in China also rose by 23% on a constant currency basi ... [Published MedNous - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

AstraZeneca PLC : Second Quarter & Half Year Results 2014

AstraZeneca PLCSECOND Quarter AND HALF YEAR Results 2014London, 31 July 2014Revenue in the second quarter was $6,454 million, up 4%* - second consecutive quarter of revenue growth. Half year revenue up 3%, driven by the five growth platforms. Core EPS ... [Published Investegate - Jul 31 2014]
First reported May 13 2014 - Updated May 13 2014 - 1 reports

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Revision: 12, Authorised

Entities: fulvestrant, Faslodex
First reported Apr 28 2014 - Updated Apr 28 2014 - 2 reports

Pfizer Confirms AstraZeneca Interest

NEW YORK (The Deal) -- New York pharmaceuticals giant Pfizer on Monday said it was considering making a renewed run at AstraZeneca AZN to strengthen its cancer treatments after a failed January approach and as rivals successfully expand their oncology ... [Published The Street Latest - Apr 28 2014]

Quotes

...measures and a reconciliation of Core to Reported financial measures Pascal Soriot, Chief Executive Officer, commenting on the results, said "We have made significant progress in the first half of the year, with visible momentum across our cardiovascular, diabetes and respiratory franchises as well as strong growth in the emerging markets. This has driven revenue growth for the second consecutive quarter and achieved a 13% increase in Core EPS in the quarter. The pace of execution of our strategy and the underlying performance of our teams give us confidence to raise 2014"
"I view a takeover of AstraZeneca by the U S drug company exceptionally skeptically" wrote Deutsche Bank AG analyst Mark Clark in a note. He has a hold rating on AstraZeneca shares...
...trials for gastric cancer, which raises the question: is there a true mechanistic difference in targeting the receptor versus the ligand? If so, "these angiogenics will start to separate themselves in terms of where they might be active" says Hawthorne. Sanofi/Regeneron haven't announced plans to test Zaltrap in gastric cancer, but http://ClinicalTrial...

More Content

All (10) | News (8) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Pfizer Submits Palbociclib Marketing Applicatio... [Published Zacks.com - Aug 19 2014]
AstraZeneca (AZN) Beats on Q2 Earnings, Guidanc... [Published Yahoo! Finance - Aug 01 2014]
AZ upgrades its forecast for 2014 [Published MedNous - Jul 31 2014]
AstraZeneca PLC : Second Quarter & Half Year Re... [Published Investegate - Jul 31 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
Pfizer Confirms AstraZeneca Interest [Published The Street Latest - Apr 28 2014]
Pfizer Confirms It Wants To Do A Blockbuster Ta... [Published Clusterstock - Apr 28 2014]
Combination treatment with strontium for the pr... [Published PharmCast - Jan 22 2014]
Higher Dose of Faslodex Effective in Advanced B... [Published BioPortfolio - Dec 30 2013]
2014 Pipeline Report: The Sprint to Value [Published Pharmaceutical Executive - Nov 08 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
Pfizer Confirms It Wants To Do A Blockbuster Ta... [Published Clusterstock - Apr 28 2014]
Here's a big, juicy M&A story to get the market excited on a Monday morning. Pharmaceutical giant Pfizer has said in a new press release that it has approached UK pharmacuetical maker AstraZeneca about a $100 billion takeover offer, but that AstraZeneca ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.